Takeda Report Results of TAK-620 (maribavir) in P-III SOLCTICE Trial for the Treatment of Post-Transplant Patients with Cytomegalovirus Infection

 Takeda Report Results of TAK-620 (maribavir) in P-III SOLCTICE Trial for the Treatment of Post-Transplant Patients with Cytomegalovirus Infection

Takeda Report Results of TAK-620 (maribavir) in P-III SOLCTICE Trial for the Treatment of Post-Transplant Patients with Cytomegalovirus Infection

Shots:

  • The P-III TAK-620-303 (SOLSTICE) trial involves assessing TAK-620 (400mg) vs conventional antiviral therapies (IAT) in HCT and SOT recipients in a ratio (2:1) with R/R CMV infection refractory with/ out resistance, to one or a combination of the conventional antiviral therapies
  • The 1EPs study shows confirmed CMV viremia clearance @ 8wk; (55% vs 26.1% in SOT recipients), (55.9% vs 20.8% in HCT recipients), CMV clearance regardless of baseline viral load category (62.1% & 43.9% vs 24.7% & 21.9%), CMV viremia clearance and symptom control in transplant recipients @16wks. (18.7% vs 10.3%)
  • Maribavir will be the 1st and only treatment indicated for post-transplant r/r CMV infection

Click here ­to­ read full press release/ article | Ref: Takeda | Image: The Boston Globe

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post